Centella asiatica Phase 1 Trial for Alzheimer's Disease (NCT05591027)
Overview
The Centella asiatica Phase 1 Clinical Trial (NCT05591027) represents an early-stage therapeutic investigation into the potential neuroprotective properties of Centella asiatica extract in Alzheimer's disease (AD) patients. This trial evaluates a botanical therapeutic derived from Centella asiatica (commonly known as Gotu kola or Indian pennywort), a traditional medicinal plant with a long history of use in Ayurvedic and traditional Chinese medicine. Phase 1 trials prioritize safety assessment, dose escalation, and preliminary bioavailability data in human subjects, establishing foundational evidence for potential progression to larger efficacy studies. The trial explores whether this plant-derived compound can modulate disease-relevant pathological processes characteristic of Alzheimer's disease, including amyloid-beta (Aβ) accumulation, tau phosphorylation, neuroinflammation, and oxidative stress.
Function/Biology
...Centella asiatica Phase 1 Trial for Alzheimer's Disease (NCT05591027)
Overview
The Centella asiatica Phase 1 Clinical Trial (NCT05591027) represents an early-stage therapeutic investigation into the potential neuroprotective properties of Centella asiatica extract in Alzheimer's disease (AD) patients. This trial evaluates a botanical therapeutic derived from Centella asiatica (commonly known as Gotu kola or Indian pennywort), a traditional medicinal plant with a long history of use in Ayurvedic and traditional Chinese medicine. Phase 1 trials prioritize safety assessment, dose escalation, and preliminary bioavailability data in human subjects, establishing foundational evidence for potential progression to larger efficacy studies. The trial explores whether this plant-derived compound can modulate disease-relevant pathological processes characteristic of Alzheimer's disease, including amyloid-beta (Aβ) accumulation, tau phosphorylation, neuroinflammation, and oxidative stress.
Function/Biology
Centella asiatica contains numerous bioactive compounds, including triterpenoids (asiaticoside, asiatic acid, madecassoside, madecassic acid), flavonoids, and phenolic acids that collectively contribute to its biological activity. These constituent compounds possess chemical properties enabling blood-brain barrier (BBB) penetration, making them potentially relevant for central nervous system (CNS) therapeutic applications. The plant extract has demonstrated multiple biological activities in preclinical studies: stimulation of nerve growth factor (NGF) production, enhancement of neuroplasticity markers, modulation of synaptic function, and neuroprotection against various cellular insults. At the cellular level, Centella asiatica components influence signaling pathways relevant to neuronal survival and stress resistance, including mitochondrial function preservation and endoplasmic reticulum stress reduction. The extract also exhibits anti-inflammatory properties through modulation of microglial activation and reduction of pro-inflammatory cytokine production.
Role in Neurodegeneration
Centella asiatica and its active metabolites have been investigated in preclinical models of neurodegenerative diseases for their potential to attenuate multiple pathogenic mechanisms. In amyloid-beta-related neurotoxicity models, the extract demonstrates neuroprotective effects through antioxidant mechanisms and potential modulation of Aβ-induced cellular dysfunction. The triterpenoid compounds show activity against tauopathy-related processes, including potential interference with tau hyperphosphorylation and aggregation pathways. Additionally, Centella asiatica exhibits effects on mitochondrial biogenesis and autophagy regulation—cellular processes frequently compromised in Alzheimer's disease pathology. The anti-neuroinflammatory properties address a significant component of AD pathogenesis, as chronic microglial activation and elevated pro-inflammatory cytokine levels (IL-1β, TNF-α, IL-6) contribute substantially to neurodegeneration.
Molecular Mechanisms
The neuroprotective mechanisms of Centella asiatica involve multiple converging pathways. Asiaticoside and related triterpenoids activate Wnt/β-catenin signaling and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathways, promoting neuronal survival and synaptogenesis. These compounds enhance expression of neurotrophic factors, particularly NGF and brain-derived neurotrophic factor (BDNF), which support neuronal integrity and cognitive function. Antioxidant mechanisms include direct free radical scavenging and enhancement of endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase). The extract modulates nuclear factor-κB (NF-κB) signaling, a master regulator of neuroinflammation, thereby reducing microglial activation and astrocytic responses. Additionally, Centella asiatica components influence autophagy through mammalian target of rapamycin (mTOR) pathway modulation, potentially enhancing clearance of misfolded proteins and pathogenic aggregates.
Clinical/Research Significance
The Phase 1 trial systematically evaluates Centella asiatica's safety profile, optimal dosing parameters, pharmacokinetics, and preliminary evidence for biological activity in Alzheimer's disease populations. Such investigations bridge traditional ethnopharmacology with modern clinical neuroscience, potentially identifying novel therapeutic candidates from botanical sources. Success in establishing safety and target engagement could justify progression to Phase 2 efficacy trials examining cognitive outcomes and biomarker responses.
- Amyloid-beta and tau protein pathology
- Neuroinflammation and microglial activation
- Blood-brain barrier penetration and drug delivery
- Neuroprotection and neuroplasticity mechanisms
- Botanical therapeutics in neurodegenerative disease
- Alternative medicine and traditional healing systems
- Biomarker assessment in Alzheimer's disease clinical trials